Consistent with our efforts to resolve our legacy compliance-related allegations, right now we're working in settlement discussions to resolve the civil suit...on speaker programs and other promotional events that happened between 2002 and 2011, we've provisioned approximately $700 million for any potential settlement.

Chief Executive Vas Narasimhan

Categorized in : Business

With respect to Zolgensma, you have to divide the total sales by the net pricing that we've achieved and also look at our U.S.-EU mix, we're in the range of 100 patients treated currently under the paid programme.

Chief Executive Vas Narasimhan

health-news

No, we will not sell Sandoz, we will make Sandoz autonomous within Novartis, so it's more competitive. Our plan is to focus Sandoz and make it better in the long-term.

Chief Executive Vas Narasimhan

business

There will be no changes here. by Chief Executive Vas Narasimhan

There will be no changes here.

Chief Executive Vas Narasimhan

business

We continue to reimagine ourselves as a leading medicines company powered by breakthrough medicines, data science and advanced therapy platforms.

Chief Executive Vas Narasimhan

company-news

A company like ours needs to focus our capital in our area of strength which I believe is innovating world class medicines and I'd like to build our strength in digital and data technologies.

Chief Executive Vas Narasimhan

business

We continue to execute our strategy to focus Novartis as a leading medicines company, alcon has returned to a position of strength and it is time to give the business more flexibility to pursue its own growth strategy.

Chief Executive Vas Narasimhan

business